Nalbuphine

CHEMBL895 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

357.4 g/mol

LogP

0.2

Phase

4

This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.

分子量

357.4000 g/mol

LogP

0.20

TPSA

73.20 Å²

Lipinski 五规则

符合

治疗领域

Pain Management Non-Small Cell Lung Cancer Asthma Generalized Anxiety Disorder Insomnia Obesity Hypertension Breast Cancer Chronic Pain Heart Failure Leukemia

作用机制

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314

InChI

InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1

Molecular Formula

C21H27NO4

HBD / HBA

3 / 5

可旋转键数

2

重原子数

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Nalbuphine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL895. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5311304. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

正在寻找患者友好型信息？

Nalbuphine 在 PillFYI 上

结构

快速数据

分子式: C21H27NO4

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.